CryoSIM Intelligent Microfluidics Platform
exploratoryplatform · high · Wed Mar 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Automate and scale high-accuracy characterization of oocyte membrane permeability to support optimization of cryopreservation protocols and broader cryobiology analytics.
Integrated microfluidic-AI workflow using Y-shaped and zigzag perfusion channels, parabolic micropillar arrays, deep-learning oocyte segmentation with MLSNet, and transport modeling with Two-Parameter and Kedem-Katchalsky models to calculate hydraulic conductivity and CPA permeability.
A 2026 publication reported CryoSIM as an integrated platform for automated, parallel oocyte permeability quantification; Yinfeng site news also references the institute's collaboration and intended expansion of the technological achievement from Jinan.
Reported 98.7% pixel-level segmentation accuracy, real-time multi-cell analysis, and more than 90% increased analytical throughput versus manual methods, with reproducible performance across biological replicates and experimental groups.
CryoSIM oocyte membrane permeability platform
exploratoryplatform · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Automate high-throughput characterization of oocyte membrane permeability parameters for cryobiology and cryopreservation protocol optimization.
Integrated microfluidic-AI platform using Y-shaped and zigzag perfusion channels, parabolic micropillar arrays, deep-learning segmentation via MLSNet, and transport modeling to calculate hydraulic conductivity and cryoprotective-agent permeability.
Published 2026 study reporting CryoSIM as a high-throughput analytical workflow for cryopreservation analytics.
Reported 98.7% pixel-level oocyte segmentation accuracy and more than 90% increase in analytical throughput over manual methods, with consistent performance across biological replicates and experimental groups.
Umbilical cord MSC-derived small extracellular vesicles for idiopathic pulmonary fibrosis
preclinicaldrug program · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop a nebulized small extracellular vesicle therapy derived from umbilical cord mesenchymal stem cells for idiopathic pulmonary fibrosis.
GMP-grade isolation of UC-sEVs, RNA-seq cargo screening, batch quality-control standardization, and pharmacodynamic testing of nebulized UC-sEV agents against bleomycin-induced pulmonary fibrosis, with focus on miR-146a-5p activity.
Published 2025 study establishing quality-control standards and validating miR-146a-5p as a potential key therapeutic molecule.
UC-sEVs inhibited pulmonary inflammatory responses by regulating macrophage function and suppressed progression of bleomycin-induced fibrosis; miR-146a-5p enrichment was implicated through TRAF6/IRAK1 inflammatory signaling regulation.
Broad-host-range PsrfA expression system in lactic acid bacteria
exploratoryplatform · medium · Sat Jan 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop and validate a broad-host-range gene expression platform in lactic acid bacteria for dairy and health-related applications.
Plasmid-based expression of GFP and heterologous enzymes under promoter PsrfA across L. casei, L. plantarum, L. fermentum, and Weissella confusa, with modulation by carbon source, nitrogen source, pH, and promoter-region mutation.
Published 2022 study demonstrating PsrfA-driven expression across multiple lactic acid bacteria species.
Recombinant strains grew well and expressed GFP; heterologous laccase CotA was expressed in L. casei and L. plantarum; pH adjustment increased CotA activity by 137.7% in L. plantarum and 61.5% in L. casei; NADH oxidase production affected fermentation pH.
Umbilical cord mesenchymal stem cell therapy for COVID-19
phase 1drug program · high · Fri Jan 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate therapeutic potential and safety of umbilical cord tissue-derived mesenchymal stem cells in patients with COVID-19.
Pilot clinical study comparing 12 patients treated with MSCs plus conventional therapy against 13 patients treated with conventional therapy alone, assessing oxygenation index, lab markers, immunoglobulin levels, CT imaging, allergic reactions, and serious adverse events.
Published 2021 pilot clinical study in COVID-19 patients.
MSC-treated patients showed significantly improved oxygenation index, significantly reduced pulmonary inflammation area, a trend toward CT-number restoration in inflammatory areas, decreased IgM levels, and no reported significant safety signal from allergic reactions or serious adverse events in the supplied abstract.
Broad-Host-Range PsrfA Expression System in Lactic Acid Bacteria
exploratoryplatform · medium
Develop a gene expression platform in lactic acid bacteria for dairy, health, and broader production applications.
Transformation of LAB strains with GFP or heterologous enzymes downstream of the broad-host-range PsrfA promoter, testing strain-specific promoter activity under different carbon, nitrogen, and pH conditions.
A 2022 publication demonstrated PsrfA-driven expression across multiple LAB species and pH-adjusted production improvements for CotA activity.
Recombinant strains grew well and expressed GFP; PsrfA enabled heterologous laccase CotA expression, with pH adjustment increasing CotA activity by 137.7% in L. plantarum 97-05 and 61.5% in L. casei 5257-05.
CryoSIM oocyte membrane permeability characterization platform
exploratoryplatform · high
Improve cryopreservation protocol optimization by automating high-throughput measurement of oocyte membrane transport parameters.
Microfluidic-AI platform using Y-shaped and zigzag perfusion channels, CPA gradients, MLSNet deep-learning segmentation, and Two-Parameter and Kedem-Katchalsky transport models to calculate hydraulic conductivity and CPA permeability.
2026 publication reported automated parallel quantification of oocyte membrane permeability with high segmentation accuracy and increased analytical throughput.
Reported 98.7% pixel-level segmentation accuracy and more than 90% increase in analytical throughput over manual methods, with reproducible performance across biological replicates and experimental groups.
Human neural stem cell-derived extracellular vesicles for hypoxia-reperfusion neuronal injury
preclinicalresearch program · medium
Investigate whether human neural stem cell-derived extracellular vesicles can protect neurons against hypoxia-reperfusion injury in vitro.
In vitro neuronal hypoxia-reperfusion injury model testing hNSC-EVs and evaluating Nrf2 nuclear translocation and downstream oxidative kinase regulation.
Published study listed in supplied filtered publications; detailed date not available in supplied material.
Supplied abstract states the project evaluated neuroprotective effects of hNSC-EVs in an in vitro neuronal hypoxia-reperfusion model through Nrf2-related oxidative signaling regulation.
Human Neural Stem Cell EV Therapy for Hypoxia-Reperfusion Injury
preclinicalresearch program · low
Investigate whether human neural stem cell-derived extracellular vesicles can protect neurons from hypoxia-reperfusion injury.
In vitro neuronal hypoxia-reperfusion injury model evaluating hNSC-EV effects on Nrf2 nuclear translocation and downstream oxidative kinase expression.
Preclinical in vitro study reported in the supplied publication abstract.
The supplied abstract states that hNSC-EVs were evaluated for neuroprotective effects through Nrf2-mediated oxidative stress regulation, but does not provide detailed quantitative outcomes in the excerpt.
Human neural stem cell extracellular vesicles for hypoxia-reperfusion injury
preclinicaldrug program · medium
Evaluate neuroprotective effects of human neural stem cell-derived extracellular vesicles against neuronal hypoxia-reperfusion injury.
In vitro neuronal hypoxia-reperfusion injury model assessing whether hNSC-EVs mediate Nrf2 nuclear translocation and downstream oxidative kinase regulation.
Publication abstract reports in vitro evaluation of hNSC-EVs in a neuronal hypoxia-reperfusion model.
Supplied abstract states the project evaluated therapeutic effect through Nrf2-mediated oxidative stress regulation, but detailed results are truncated.
Nebulized UC-sEV Therapy for Idiopathic Pulmonary Fibrosis
preclinicaldrug program · medium
Develop quality-controlled umbilical cord mesenchymal stem cell-derived small extracellular vesicles as a potential therapy for idiopathic pulmonary fibrosis by reducing inflammation and fibrosis.
GMP-grade isolation of UC-sEVs, RNA-seq screening for therapeutic cargo, nebulized administration in IPF disease models, and quality control based on batch stability and miRNA profiles.
A 2025 publication established a GMP-grade process, proposed quality control standards, and identified miR-146a-5p-enriched UC-sEVs as a candidate therapeutic product for IPF.
UC-sEVs inhibited pulmonary inflammatory response, regulated macrophage function, suppressed bleomycin-induced fibrosis progression, and implicated miR-146a-5p targeting TRAF6/IRAK1 as a mechanism.
PsrfA lactic acid bacteria expression system
exploratoryplatform · medium
Develop a broad-host-range promoter system for gene expression in lactic acid bacteria for dairy and health applications.
Expression plasmids placing GFP, CotA laccase, or NADH oxidase downstream of promoter PsrfA or derivatives in multiple LAB strains, with media and pH optimization.
2022 publication showed PsrfA-driven expression across L. casei, L. plantarum, L. fermentum, and Weissella confusa strains.
Recombinant strains displayed detectable fluorescence; CotA activity increased after pH adjustment; PsrfA was described as valid for gene expression in different LAB species.
UC-sEV therapy for idiopathic pulmonary fibrosis
preclinicaldrug program · high
Treat idiopathic pulmonary fibrosis by reducing pulmonary inflammation and fibrosis using umbilical cord mesenchymal stem cell-derived small extracellular vesicles.
GMP-grade UC-sEV isolation, RNA-seq cargo characterization, nebulized UC-sEV administration, and quality-control standards focused on miR-146a-5p enrichment.
2025 publication established a GMP-grade process and proposed quality control standards for nebulized UC-sEV therapy in IPF models.
UC-sEVs inhibited pulmonary inflammatory response and fibrosis progression in bleomycin-induced models; miR-146a-5p was implicated via TRAF6/IRAK1 inflammatory regulation.
Umbilical cord MSC therapy for COVID-19
exploratorydrug program · medium
Assess whether umbilical cord mesenchymal stem cells can safely improve lung injury and clinical markers in patients with COVID-19.
Pilot clinical study comparing MSC infusion plus conventional therapy against conventional therapy alone in hospitalized COVID-19 patients.
2021 pilot study included 12 MSC-treated patients and 13 controls.
MSC-treated patients showed significantly improved oxygenation index, reduced pulmonary inflammation area, decreased IgM levels, and no reported serious safety signal in the supplied abstract.
Umbilical Cord MSC Therapy for COVID-19
phase 1drug program · medium
Evaluate the therapeutic potential and safety of umbilical cord mesenchymal stem cells for patients with COVID-19.
Pilot clinical study comparing 12 COVID-19 patients receiving MSCs plus conventional therapy with 13 patients receiving conventional therapy alone, assessing oxygenation index, labs, immunoglobulin levels, pulmonary CT imaging, allergic reactions, and serious adverse events.
A 2021 pilot study reported clinical evaluation of MSC infusion in COVID-19 patients.
MSC-treated patients showed significantly improved oxygenation index, decreased pulmonary inflammation area, trends toward restored CT number in inflammatory areas, decreased IgM levels, and no serious safety signal reported in the supplied abstract.
Yinfeng Life Extension Program
exploratoryresearch program · high
Research and develop low-temperature preservation and reheating techniques for large-sized intact organisms, including human body cryopreservation and related life science research.
Technology-driven, multidisciplinary cryomedicine research program spanning low-temperature biomedical science, clinical medicine, regenerative medicine, artificial intelligence, brain-computer interface, law, ethics, and psychology.
Program public materials describe ongoing scientific research, expert team activity, collaboration and exchange, and expansion of transformation/application plans centered in Jinan.
